Neuromodulation in the Treatment of Migraine: Progress in Nerve Stimulation
DOI:
https://doi.org/10.17140/NOJ-3-122Keywords:
Neuromudulation, Migraine treatment, Nerve stimulationAbstract
Migraine is a type of primary headache disorder that can become chronic and disabling. The exact pathomechanism of migraine is not known very well and its treatment is also difficult in some cases. There are several medications for the acute and preventive treatment of migraine including the “triptan” family drugs, nonsteroidal anti-inflammatory drugs, anti-epileptic drugs, beta-blockers, and Ca2+ channel blockers1 and those against calcitonin gene-related peptide or its receptor that are reviewed elsewhere. However, there are some medically intractable headaches or patient management is unsatisfactory or medications are poorly tolerated or there are contraindications. Therefore, neuromodulation and nerve stimulation methods that have proven effective in clinical research may provide an additional treatment option for acute and preventive treatment of migraine. In this brief review, we will discuss recent advances using neuromodulatory techniques that are currently used in the treatment of headaches in clinical studies. These include the electrical stimulation of occipital nerve, sphenopalatine ganglion, supraorbital nerve, and transcutaneous electrical stimulation of vagus nerve as well as singlepulse transcranial magnetic stimulation. Several clinical studies have conducted neurostimulation for the acute and preventive treatment of migraine in recent years but more studies are necessary to see their efficacy and long-term effect.
References
Evers S, Afra J, Frese A, et al. EFNS guideline on the drug treatment of migraine – revised report of an EFNS task force. Eur J Neurol. 2009; 16: 968-981. doi: 10.1111/j.1468- 1331.2009.02748.x
Samsam M. Drugs against calcitonin gene-related peptide and its receptor used in the treatment of migraine: What are the new progresses? Neuro Open J. 2015; 2: 79-91. doi: 10.17140/NOJ-2-117
Diener HC, Charles A, Goadsby PJ, Holle D. New therapeu-tic approaches for the prevention and treatment of migraine. Lancet Neurol. 2015; 14(10): 1010-1022. doi: 10.1016/S1474- 4422(15)00198-2
Weiller C, May A, Limmroth V, et al. Brain stem activation in spontaneous human migraine attacks. Nat Med. 1995; 1: 658- 660. doi: 10.1038/nm0795-658
Cohen AS, Goadsby PJ. Functional neuroimaging of primary headache disorders. Expert Rev Neurother. 2006; 6: 1159-1171. doi: 10.1586/14737175.6.8.1159
Goadsby PJ. Recent advances in understanding migraine mechanisms, molecules and therapeutics. Trends Mol Med. 2007; 13: 39-44. doi: 10.1016/j.molmed.2006.11.005
Akerman S, Holland PR, Goadsby PJ. Diencephalic and brain-stem mechanisms in migraine. Nat Rev Neurosci. 2011; 12: 570- 584. doi: 10.1038/nrn3057
Samsam M. Central nervous system acting drugs in treatment of migraine headache. Cent Nerv Syst Agents Med Chem. 2012; 12: 158-172. doi: 10.2174/187152412802430147
Lauritzen M. Pathophysiology of the migraine aura. The spreading depression theory. Brain. 1994; 117 (Pt 1): 199-210. doi: 10.1093/brain/117.1.199
Tfelt-Hansen PC. History of migraine with aura and corti-cal spreading depression from 1941 and onwards. Cephalalgia. 2010; 30(7): 780-92. doi: 10.1111/j.1468-2982.2009.02015.x
Lauritzen M, Strong AJ. ‘Spreading depression of Leão’ and its emerging relevance to acute brain injury in humans. J Cereb Blood Flow Metab. 2016; pii: 0271678X16657092. doi: 10.1177/0271678X16657092
Ophoff RA, Terwindt GM, Vergouwe MN, et al. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell. 1996; 87: 543-552. doi: 10.1016/S0092-8674(00)81373-2
De Fusco M, Marconi R, Silvestri L, et al. Haploinsuffi-ciency of ATP1A2 encoding the Na+/K+ pump alpha2 subunit associated with familial hemiplegic migraine type 2. Nat Genet 2003; 33: 192-196. doi: 10.1038/ng1081
Vanmolkot KR, Kors EE, Hottenga JJ, et al. Novel mutations in the Na+, K+-ATPase pump gene ATP1A2 associated with fa-milial hemiplegic migraine and benign familial infantile convul-sions. Ann Neurol. 2003; 54: 360-366. doi: 10.1002/ana.10674
Dichgans M, Freilinger T, Eckstein G, et al. Mutation in the neuronal voltage-gated sodium channel SCN1A in familial hemiplegic migraine. Lancet. 2005; 366: 371-377. doi: 10.1016/ S0140-6736(05)66786-4
Kors EE, Vanmolkot KR, Haan J, et al. Recent findings in hea-dache genetics. Curr Opin Neurol. 2004; 17: 283-288. Web site. http://journals.lww.com/co-neurology/Abstract/2004/06000/Re-cent_findings_in_headache_genetics.8.aspx. Accessed Decem-ber 27, 2016.
van den Maagdenberg AM, Pietrobon D, Pizzorusso T, et al. A Cacna1a knockin migraine mouse model with increased sus-ceptibility to cortical spreading depression. Neuron. 2004; 41: 701-710. doi: 10.1016/S0896-6273(04)00085-6
Olsen J. Headache Classification Subcommittee of the In-ternational Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia. 2004; 241: 9-160.
Ferrari MD, Klever RR, Terwindt GM, Ayata C, van den Maagdenberg AM. Migraine pathophysiology: lessons from mouse models and human genetics. Lancet Neurol. 2015; 14(1): 65-80. doi: 10.1016/S1474-4422(14)70220-0
Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia. 2013; 33(9): 629-808.
Gallai V, Sarchielli P, Floridi A, et al. Vasoactive peptide lev-els in the plasma of young migraine patients with and without aura assessed both interictally and ictally. Cephalalgia. 1995; 15(5): 384-390. doi: 10.1046/j.1468-2982.1995.1505384.x
Olesen J, Diener HC, Husstedt IW, et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med. 2004; 350(11): 1104-1110. doi: 10.1056/NEJMoa030505
Iovino M, Feifel U, Yong CL, Wolters JM, Wallenstein G. Safety, tolerability and pharmacokinetics of BIBN 4096 BS, the first selective small molecule calcitonin gene-related peptide receptor antagonist, following single intravenous administra-tion in healthy volunteers. Cephalalgia. 2004; 24: 645-656. doi: 10.1111/j.1468-2982.2004.00726.x
Ho TW, Ferrari MD, Dodick DW, et al. Efficacy and toler-ability of MK-0974 (telcagepant), a new oral antagonist of calci-tonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: A randomised, placebo-controlled, parallel-treatment trial. Lancet. 2008; 372: 2115-2123. doi: 10.1016/ S0140-6736(08)61626-8
Ho TW, Mannix LK, Fan X, et al. MK-0974 Protocol 004 study group. Collaborators (20), Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology. 2008; 70: 1304-1312. doi: 10.1212/01. WNL.0000286940.29755.61
Connor KM, Shapiro RE, Diener HC, et al. Random-ized, controlled trial of telcagepant for the acute treatment of migraine. Neurology. 2009; 73: 970-977. doi: 10.1212/ WNL.0b013e3181b87942
Salvatore CA, Moore EL, Calamari A, et al. Pharmacologi-cal properties of MK-3207, a potent and orally active calcitonin gene-related peptide receptor antagonist. J Pharmacol Exp Ther. 2010; 333: 152-160. doi: 10.1124/jpet.109.163816
Hewitt DJ, Aurora SK, Dodick DW, et al. Randomized con-trolled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine. Cephalalgia. 2011; 31: 712-722. doi: 10.1177/0333102411398399
Diener HC, Barbanti P, Dahlöf C, et al. BI44370TA, an oral CGRP antagonist for the treatment of acute migraine attacks: Results from a phase II study. Cephalalgia. 2011; 31: 573-84. doi: 10.1177/0333102410388435
Leahy DK, Fan Y, Desai LV, et al. Efficient and scalable en-antioselective synthesis of a CGRP antagonist. Org Lett. 2012; 14: 4938-4941. doi: 10.1021/ol302262q
Luo G, Chen L, Conway CM, et al. Discovery of BMS-846372, a Potent and Orally Active Human CGRP Receptor An-tagonist for the Treatment of Migraine. ACS Med Chem Lett. 2012; 3: 337-341. doi: 10.1021/ml300021s
Voss T, Lipton RB, Dodick DW, et al. A phase IIb random-ized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine. Cephalalgia. 2016; 36: 887-898. doi: 10.1177/0333102416653233
Dodick DW, Goadsby PJ, Spierings EL, Scherer JC, Swee-ney SP, Grayzel DS. Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: A phase 2, randomized, double-blind, placebo-controlled study. Lancet Neurol. 2014; 13: 885-892. doi: 10.1016/S1474-4422(14)70128-0
Dodick DW, Goadsby PJ, Silberstein SD, et al. ALD403 study investigators. Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: A randomized, double-blind, placebo-con-trolled, exploratory phase 2 trial. Lancet Neurol. 2014; 13(11): 1100-1107. doi: 10.1016/S1474-4422(14)70209-1
Bigal ME, Escandon R, Bronson M, et al. Safety and tol-erability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: Results of the Phase 1 program.Cephalalgia. 2013; 34(7): 483-492. doi: 10.1177/033310241351777
Bigal ME, Dodick DW, Krymchantowski AV, et al. TEV-48125 for the preventive treatment of chronic migraine: Effi-cacy at early time points. Neurology. 2016; 87(1): 41-88. doi: 10.1212/WNL.0000000000002801
BigalME, Walter S, Rapoport AM. Therapeutic antibodies against CGRP or its receptor. Br J Clin Pharmacol. 2015; 79(6): 886-895. doi: 10.1111/bcp.12591
Ferrari MD, Färkkilä M, Reuter U, et al. European COL-144 Investigators. Acute treatment of migraine with the se-lective 5-HT1F receptor agonist lasmiditan--a randomized proof-of-concept trial. Cephalalgia. 2010; 30: 1170-1178. doi: 10.1177/0333102410375512
Nelson DL, Phebus LA, Johnson KW, et al. Preclini-cal pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan. Cephalalgia. 2010; 30: 1159-1169. doi: 10.1177/0333102410370873
Färkkilä M, Diener HC, Géraud G, et al. COL MIG-202 study group. Efficacy and tolerability of lasmiditan, an oral 5-HT(1F) receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-rang-ing study. Lancet Neurol. 2012; 11(5): 405-413. doi: 10.1016/ S1474-4422(12)70047-9
Hoffmann J, Goadsby PJ. Emerging targets in migraine. CNS Drugs. 2014; 28: 11-17. doi: 10.1007/s40263-013-0126-2
Karsan N, Goadsby PJ. CGRP mechanism antagonists and migraine management. Curr Neurol Neurosci Rep. 2015; 15(5): 25. doi: 10.1007/s11910-015-0547-z
Antonaci F, Ghiotto N, Wu S, Pucci E, Costa A. Recent ad-vances in migraine therapy. Springerplus. 2016; 5: 637. doi: 10.1186/s40064-016-2211-8
Starling AJ, Vargas BB. A narrative review of evidence-based preventive options for chronic migraine. Curr Pain Head-ache Rep. 2015; 19(10):49. doi: 10.1007/s11916-015-0521-0
Picaza JA, Cannon BW, Hunter SE, Boyd AS, Guma J, Mau-rer D. Pain suppression by peripheral nerve stimulation. Part I. Observations with transcutaneous stimuli. Surg Neurol. 1975; 4(1): 105-114. doi: 10.1159/000102446
Picaza JA, Cannon BW, Hunter SE, Boyd AS, Guma J, Mau-rer D. Pain suppression by peripheral nerve stimulation. Part II. Observations with implanted devices. Surg Neurol. 1975; 4(1): 115-126.
Picaza JA, Hunter SE, Cannon BW. Pain suppression by peripheral nerve stimulation. Chronic effects of implanted de-vices. Appl Neurophysiol. 1977-1978; 40(2-4): 223-234. doi: 10.1159/000102446
Lou L. Uncommon areas of electrical stimulation for pain re-lief. Curr Rev Pain. 2000; 4(5): 407-412. doi: 10.1007/s11916- 000-0025-3
Van Calenbergh F, Gybels J, Van Laere K, et al. Long term clinical outcome of peripheral nerve stimulation in patients with chronic peripheral neuropathic pain. Surg Neurol. 2009; 72(4): 330-335. doi: 10.1016/j.surneu.2009.03.006
Stanton-Hicks M, Salamon J. Stimulation of the central and peripheral nervous system for the control of pain. J Clin Neuro-physiol. 1997; 14(1): 46-62.
Stojanovic MP. Stimulation methods for neuropathic pain control. Curr Pain Headache Rep. 2001; 5(2): 130-137. doi: 10.1007/s11916-001-0081-3
Goadsby PJ, Zagami AS, Lambert GA. Neural processing of craniovascular pain: A synthesis of the central structures in-volved in migraine. Headache. 1991; 31(6): 365-371.
Weiner RL, Reed KL. Peripheral neurostimulation for con-trol of intractable occipital neuralgia. Neuromodulation. 1999; 2(3): 217-221. doi: 10.1046/j.1525-1403.1999.00217.x
Nörenberg E, Winkelmüller W. The epifacial electric stimu-lation of the occipital nerve in cases of therapy-resistant neural-gia of the occipital nerve. Schmerz. 2001; 15(3): 197-199.
Saper JR, Dodick DW, Silberstein SD, McCarville S, Sun M, Goadsby PJ, ONSTIM Investigators. Occipital nerve stimulation for the treatment of intractable chronic migraine headache: ON-STIM feasibility study. Cephalalgia. 2011; 31(3): 271-285. doi: 10.1177/0333102410381142
Silberstein SD, Dodick DW, Saper J, et al. Safety and ef-ficacy of peripheral nerve stimulation of the occipital nerves for the management of chronic migraine: Results from a random-ized, multicenter, double-blinded, controlled study. Cephalalgia. 2012; 32(16): 1165-1179. doi: 10.1177/0333102412462642
Miller S, Watkins L, Matharu M. Long-term outcomes of occipital nerve stimulation for chronic migraine: A cohort of 53 patients. J Headache Pain. 2016; 17(1): 68. doi: 10.1186/ s10194-016-0659-0
Clark SW, Venkatesan L, Boorman D, et al. 189 Comparison of efficacy of tonic and burst occipital nerve stimulation in treat-ing trigeminal allodynia: Chronic Result. Neurosurgery. 2016; 63(Suppl 1): 175. doi: 10.1227/01.neu.0000489758.97532.6a
Slotty PJ, Bara G, Kowatz L, et al. Occipital nerve stim-ulation for chronic migraine: A randomized trial on sub-threshold stimulation. Cephalalgia. 2015; 35(1): 73-78. doi: 10.1177/0333102414534082
Khan S, Schoenen J, Ashina M. Sphenopalatine ganglion neuromodulation in migraine: What is the rationale? Cephalal-gia. 2014; 34(5): 382-391. doi: 10.1177/0333102413512032
Piagkou M, Demesticha T, Troupis T, et al. The pterygo-palatine ganglion and its role in various pain syndromes: From anatomy to clinical practice. Pain Pract. 2012; 12(5): 399-412. doi: 10.1111/j.1533-2500.2011.00507.x
Klein RN, Burk DT, Chase PF. Anatomically and physi-ologically based guidelines for use of the sphenopalatine ganglion block versus the stellate ganglion block to re-duce atypical facial pain. Cranio. 2001; 19(1): 48-55. doi: 10.1080/08869634.2001.11746151
Schoenen J. Sphenopalatine ganglion stimulation in neuro-vascular headaches. Prog Neurol Surg. 2015; 29: 106-116. doi: 10.1159/000434661
Goadsby PJ. Sphenopalatine ganglion stimulation increases regional cerebral blood flow independent of glucose utilization in the cat. Brain Res. 1990; 506(1): 145-148. doi: 10.1016/0006- 8993(90)91211-X
Tepper SJ, Rezai A, Narouze S, Steiner C, Mohajer P, An-sarinia M. Acute treatment of intractable migraine with spheno-palatine ganglion electrical stimulation. Headache. 2009; 49(7): 983-989. doi: 10.1111/j.1526-4610.2009.01451.x
Fox EJ, Melzack R. Transcutaneous electrical stimulation and acupuncture: Comparison of treatment for low-back pain. Pain. 1976; 2(2): 141-148. doi: 10.1016/0304-3959(76)90109-3
Magora F, Aladjemoff L, Tannenbaum J, Magora A. Treat-ment of pain by transcutaneous electrical stimulation. Acta An-aesthesiol Scand. 1978; 22(6): 589-592. doi: 10.1111/j.1399- 6576.1978.tb01341.x
Cook IA, Abrams M, Leuchter AF. Trigeminal nerve stimu-lation for comorbid posttraumatic stress disorder and major de-pressive disorder. Neuromodulation. 2016; 19(3): 299-305. doi: 10.1111/ner.12399
Schoenen J, Roberta B, Magis D, Coppola G. Noninvasive neurostimulation methods for migraine therapy: The available evidence. Cephalalgia. 2016; pii: 0333102416636022. doi: 10.1177/0333102416636022
Schoenen J, Vandersmissen B, Jeangette S, et al. Migraine prevention with a supraorbital transcutaneous stimulator: A ran-domized controlled trial. Neurology. 2013; 80(8): 697-704. doi: 10.1212/WNL.0b013e3182825055
Riederer F, Penning S, Schoenen J. Transcutaneous supra-orbital nerve stimulation (t-SNS) with the Cefaly® device for migraine prevention: A Review of the available data. Pain Ther. 2015; 4(2): 135-147. doi: 10.1007/s40122-015-0039-5
Russo A, Tessitore A, Conte F, et al. Transcutaneous supraor-bital neurostimulation in “de novo” patients with migraine with-out aura: The first Italian experience. J Headache Pain. 2015; 16: 69. doi: 10.1186/s10194-015-0551-3
Magis D, Sava S, d’Elia TS, Baschi R, Schoenen J. Safety and patients’ satisfaction of transcutaneous supraorbital neurostimu-lation (tSNS) with the Cefaly® device in headache treatment: A survey of 2,313 headache sufferers in the general population. J Headache Pain. 2013; 14: 95. doi: 10.1186/1129-2377-14-95
Magis D, D’Ostilio K, Thibaut A, et al. Cerebral metabo-lism before and after external trigeminal nerve stimulation in episodic migraine. Cephalalgia. 2016. pii: 0333102416656118. doi: 10.1177/0333102416656118
Vonck K, Van Laere K, Dedeurwaerdere S, et al. The mecha-nism of action of vagus nerve stimulation for refractory epilepsy: The current status. J Clin Neurophysiol. 2001; 18(5): 394-401.
Vonck K, Boon P, Van Roost D. Anatomical and physi-ological basis and mechanism of action of neurostimulation for epilepsy. Acta Neurochir Suppl. 2007; 97(Pt 2): 321-328. 10.1007/978-3-211-33081-4_35
Bohning DE, Lomarev MP, Denslow S, Nahas Z, Shastri A, George MS. Feasibility of vagus nerve stimulation-synchro-nized blood oxygenation level-dependent functional MRI. Invest Radiol. 2001; 36(8): 470-479.
Ko D, Heck C, Grafton S, et al. Vagus nerve stimulation activates central nervous system structures in epileptic patients during PET H2(15)O blood flow imaging. Neurosurgery. 1996; 39(2): 426-430.
Henry TR, Bakay RA, Votaw JR, et al. Brain blood flow alterations induced by therapeutic vagus nerve stimulation in partial epilepsy: I. Acute effects at high and low levels of stimu-lation. Epilepsia. 1998; 39(9): 983-990.
Narayanan JT, Watts R, Haddad N, Labar DR, Li PM, Filippi CG. Cerebral activation during vagus nerve stimulation: A func-tional MR study. Epilepsia. 2002; 43(12): 1509-1514.
Hord ED, Evans MS, Mueed S, Adamolekun B, Naritoku DK. The effect of vagus nerve stimulation on migraines. J Pain. 2003; 4(9): 530-534. doi: 10.1016/j.jpain.2003.08.001
Mauskop A. Vagus nerve stimulation relieves chronic refrac-tory migraine and cluster headaches. Cephalalgia. 2005; 25(2): 82-86. doi: 10.1111/j.1468-2982.2005.00611.x
Cecchini AP, Mea E, Tullo V, et al. Vagus nerve stimulation in drug-resistant daily chronic migraine with depression: Prelim-inary data. Neurol Sci. 2009; 30(1): S101-S104. doi: 10.1007/ s10072-009-0073-3
Mosqueira AJ, López-Manzanares L, Canneti B, et al. Vagus nerve stimulation in patients with migraine. Rev Neurol. 2013; 57(2): 57-63.
Ness TJ, Fillingim RB, Randich A, Backensto EM, Faught E. Low intensity vagal nerve stimulation lowers human thermal pain thresholds. Pain. 2000; 86(1-2): 81-85.
Chen SP, Ay I, de Morais AL, et al. Vagus nerve stimulation inhibits cortical spreading depression. Pain. 2016; 157(4): 797- 805. doi: 10.1097/j.pain.0000000000000437
Goadsby PJ, Grosberg BM, Mauskop A, Cady R, Simmons KA. Effect of noninvasive vagus nerve stimulation on acute mi-graine: An open-label pilot study. Cephalalgia. 2014; 34(12): 986-993. doi: 10.1177/0333102414524494
Barbanti P, Grazzi L, Egeo G, et al. Non-invasive vagus nerve stimulation for acute treatment of high-frequency and chronic migraine: An open-label study. J Headache Pain. 2015; 16: 61. doi: 10.1186/s10194-015-0542-4
Straube A, Ellrich J, Eren O, Blum B, Ruscheweyh R. Treat-ment of chronic migraine with transcutaneous stimulation of the auricular branch of the vagal nerve (auricular t-VNS): A ran-domized, monocentric clinical trial. J Headache Pain. 2015; 16: 543. doi: 10.1186/s10194-015-0543-3
Kinfe TM, Pintea B, Muhammad S, et al. Cervical non-invasive vagus nerve stimulation (nVNS) for preventive and acute treatment of episodic and chronic migraine and migraine-associated sleep disturbance: A prospective observational cohort study. J Headache Pain. 2015; 16: 101. doi: 10.1186/s10194- 015-0582-9
Silberstein SD, Calhoun AH, Lipton RB, et al. EVENT Study Group. Chronic migraine headache prevention with noninvasive vagus nerve stimulation: The EVENT study. Neurology. 2016; 87(5): 529-538. doi: 10.1212/WNL.0000000000002918
Gaul C, Diener HC, Silver N, et al. PREVA Study Group. Non-invasive vagus nerve stimulation for PREVention and Acute treatment of chronic cluster headache (PREVA): A ran-domised controlled study. Cephalalgia. 2016; 36(6): 534-546. doi: 10.1177/0333102415607070
Knyihár-Csillik E, Tajti J, Samsam M, Sáry G, Slezák S, Vécsei L. Effect of a serotonin agonist (sumatriptan) on the pep-tidergic innervation of the rat cerebral dura mater and on the expression of c-fos in the caudal trigeminal nucleus in an experi-mental migraine model. J Neurosci Res. 1997; 48(5): 449-464.
Samsam M, Coveñas R, Ahangari R, Yajeya J, Narváez JA, Tramu G. Simultaneous depletion of neurokinin A, substance P and calcitonin gene-related peptide from the caudal trigeminal nucleus of the rat during electrical stimulation of the trigeminal ganglion. Pain. 2000; 84(2-3): 389-395.
Samsam M, Coveñas R, Csillik B, et al. Depletion of sub-stance P, neurokinin A and calcitonin gene-related peptide from the contralateral and ipsilateral caudal trigeminal nucleus fol-lowing unilateral electrical stimulation of the trigeminal gan-glion; A possible neurophysiological and neuroanatomical link to generalized head pain. J Chem Neuroanat. 2001; 21(2): 161- 169. doi: 10.1016/S0891-0618(01)00088-6
Koopman FA, Chavan SS, Miljko S, et al. Vagus nerve stim-ulation inhibits cytokine production and attenuates disease se-verity in rheumatoid arthritis. Proc Natl Acad Sci U S A. 2016; 113(29): 8284-8289. doi: 10.1073/pnas.1605635113
Rösler KM, Hess CW, Schmid UD. Investigation of facial motor pathways by electrical and magneticstimulation: Sites and mechanisms of excitation. J Neurol Neurosurg Psychiatry. 1989; 52(10): 1149-1156.
Mills KR, Murray NM, Hess CW. Magnetic and electrical transcranial brain stimulation: Physiological mechanisms and clinical applications. Neurosurgery. 1987; 20(1): 164-168.
Lo YL. Headache: Migraine, magnetic stimulation and cor-tical excitability. Nat Rev Neurol. 2010; 6(8): 425-427. doi: 10.1038/nrneurol.2010.109
Bhola R, Kinsella E, Giffin N, et al. Single-pulsetranscra-nial magnetic stimulation (sTMS) for the acute treatment of migraine: Evaluation of outcome data for the UK post market pilot program. J Headache Pain. 2015; 16: 535. doi: 10.1186/ s10194-015-0535-3
Lipton RB, Dodick DW, Silberstein SD, et al. Single-pul-setranscranial magnetic stimulation for acute treatment of mi-graine with aura: A randomised, double-blind, parallel-group, sham-controlled trial. Lancet Neurol. 2010; 9(4): 373-380. doi: 10.1016/S1474-4422(10)70054-5
Andreou AP, Holland PR, Akerman S, Summ O, Fredrick J, Goadsby PJ. Transcranial magnetic stimulation and potential cortical and trigeminothalamic mechanisms in migraine. Brain. 2016; 139(Pt 7): 2002-2014. doi: 10.1093/brain/aww118
Dodick DW, Schembri CT, Helmuth M, Aurora SK. Transcranial magnetic stimulation for migraine: A safety re-view. Headache. 2010; 50(7): 1153-1163. doi: 10.1111/j.1526- 4610.2010.01697.x
Lipton RB, Buse DC, Serrano D, Holland S, Reed ML. Ex-amination of unmet treatment needs among persons with episod-ic migraine: Results of the American Migraine Prevalence and Prevention (AMPP) Study. Headache. 2013; 53(8): 1300-1311. doi: 10.1111/head.12154
Lipton RB, Serrano D, Nicholson RA, Buse DC, Runken MC, Reed ML. Impact of NSAID and Triptan use on developing chronic migraine: Results from the American Migraine Preva-lence and Prevention (AMPP) study. Headache. 2013; 53(10): 1548-1563. doi: 10.1111/head.12201
Berger A, Bloudek LM, Varon SF, Oster G. Adherence with migraine prophylaxis in clinical practice. Pain Pract. 2012; 12(7): 541-549. doi: 10.1111/j.1533-2500.2012.00530.x
Schuster NM, Rapoport AM. New strategies for the treat-ment and prevention of primary headache disorders. Nat Rev Neurol. 2016; 12(11): 635-650. doi: 10.1038/nrneurol.2016.143
Magis D, Bruno MA, Fumal A, et al. Central modulation in cluster headache patients treated with occipital nerve stim-ulation: An FDG-PET study. BMC Neurol. 2011; 11: 25. doi: 10.1186/1471-2377-11-25
Samsam M, Coveñas R, Ahangari R, Yajeya J. Neuropep-tides and other chemical mediators, and the role of anti-inflam-matory drugs in primary headaches. AIAA-MC. 2010; 3: 170- 188. doi: 10.2174/1871523011009030170
Contreras RJ, Beckstead RM, Norgren R. The central pro-jections of the trigeminal, facial, glossopharyngeal and vagus nerves: An autoradiographic study in the rat. J Auton Nerv Syst. 1982; 6(3): 303-322.
Lyubashina OA, Sokolov AY, Panteleev SS. Vagal affer-ent modulation of spinal trigeminal neuronal responses to dural electrical stimulation in rats. Neuroscience. 2012; 222: 29-37. doi: 10.1016/j.neuroscience.2012.07.011
Bossut DF, Maixner W. Effects of cardiac vagal afferent electrostimulation on the responses of trigeminal and trigemino-thalamic neurons to noxious orofacial stimulation. Pain. 1996; 65(1): 101-119.
Puledda F, Goadsby PJ. Current approaches to neuromodu-lation in primary headaches: Focus on vagal nerve and spheno-palatine ganglion stimulation. Curr Pain Headache Rep. 2016; 20(7): 47. doi: 10.1007/s11916-016-0577-5
Martelletti P, Jensen RH, Antal A, et al. European Headache Federation. Neuromodulation of chronic headaches: Position statement from the European Headache Federation. J Headache Pain. 2013; 14: 86. doi: 10.1186/1129-2377-14-86 Neuro Open J Page 22
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Neuro (NEURO) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.